
Could protein bars with added collagen help with weight loss?
New research explores the potential of protein bars enriched with collagen as a weight loss aid. Jeff Wasserman/Stocksy A study conducted by Spanish researchers analyzed how effective collagen is as a weight loss aid.
The study followed two groups for 12 weeks; one group received collagen-based protein bars, and the other did not.
The group that received the collagen supplement lost twice as much weight as the control group.
More than 70% of adults in the U.S. are either overweight or have obesity. As this number continues to climb, scientists are interested in finding ways to help people lose weight.
There are many popular weight loss options, such as GLP-1 drugs, but these can be cost-prohibitive for many people.
With that in mind, researchers in the new study took a closer look at the supplement collagen. Since collagen is relatively inexpensive, the researchers wondered how people who used a collagen supplement for a 12-week period would do compared to a control group.
The results showed promise for the future of using collagen supplements as a weight-loss aid, the collagen group saw a greater improvement across multiple health metrics.
The findings of the study appear in Nutrients.
Collagen is a protein found in the connective tissue of both humans and animals. Collagen supplements are often derived from cows or pigs and are widely available in pill and powder form.
Collagen has many benefits and can be helpful for improving joint health and building muscle mass. It is also beneficial for improving skin elasticity.
The supplement is gaining attention as a potential weight loss tool, and researchers in the present study wanted to see how adding a collagen supplement to one's diet could affect weight loss.
The researchers recruited 64 adults for their study, whose BMI levels ranged from being overweight to class 1 obesity.
The participants followed a healthy diet similar to the Mediterranean diet, which focuses on whole foods such as fruits, vegetables, whole grains, healthy fats, and fish and poultry.
The test group (32 people) received a protein bar to eat in addition to their meals twice per day. The 90-calorie protein bars had 10 grams of bovine-based collagen.
The control group did not receive a placebo bar and only focused on following the dietary recommendations.
The control group consumed around 2000 calories per day while the control group consumed slightly more because of the protein bars.
The participants went to several screening appointments to provide their weight, blood pressure, blood samples, and urine and fecal samples. They also completed questionnaires about their food intake and appetite.
The study results are promising for people who want to lose weight.
Not only did the collagen group have a greater weight loss than the control group, they showed improvement in cardiometabolic health.
Participants in the collagen group lost an average of 6.6 pounds compared to the control group where participants lost an average of 3.3 pounds.
The test group saw a greater decrease in systolic blood pressure with readings reduced by 8 mm Hg on average compared to a slight rise of 0.4 mm Hg in the control group. The test group also experienced bigger reductions in waist circumference, BMI, and fatty liver index .
While muscle loss is a concern with weight loss, the participants did not have this issue. The test group had a higher fat-free mass at the end of the study.
The test group participants also reported reduced hunger and an increased feeling of being full with their protein bars.
The collagen group noticed this feeling of satiety throughout the entire study. They reported the same experience when they went to screenings at months 1, 2, and 3.
Overall, the study makes an excellent case for using collagen supplements as a cost-effective way of enhancing weight loss.
A study limitation exists in that some of the authors are affiliated with the company that produces the protein bars.
Mir Ali, MD, a board certified general surgeon, bariatric surgeon, and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center spoke with Medical News Today about the study.
'This was a good study that showed the potential benefits of protein bars with collagen,' said Ali.
Ali noted that there may be some question of whether the collagen itself was responsible for the weight loss.
'I am not certain that the effects can all be attributed to collagen as protein meal replacements are also beneficial to weight loss,' commented Ali, who said more research is needed on this.
When asked whether there are any health concerns people should have about using collagen supplements, Ali did not think most people would have anything to worry about. Possible side effects with collagen
'I am not aware of any major concern with collagen supplements; perhaps a bloating sensation as collagen swells when ingested. Patients with poor gastric motility may feel more bloating, but overall collagen appears safe.'
— Mir Ali, MD
Hector Perez, MD, lead bariatric surgeon at Renew Bariatrics, also spoke with MNT .
'It's a promising and well-structured pilot study,' said Perez. 'The randomized controlled design, use of validated tools (like DEXA), and a focus on both subjective (appetite) and objective (weight, fat-free mass, metabolic markers) outcomes are strengths.'
Perez also said collagen supplements are generally safe but did say people with kidney disease need to proceed with care. Is collagen safe for everyone?
'There's a theoretical concern about kidney strain in people with impaired renal function if high protein supplements are overused, though this study's dosage (20g/day) is moderate.'
— Hector Perez, MD
While Perez finds the study promising, he did say collagen is not a 'magic bullet.'
'I'd recommend collagen as a complement to a structured weight loss program, not as a stand-alone solution,' said Perez. 'I always stress that no supplement replaces portion control, physical activity, and sustainable dietary habits.'
Nutrition / Diet
Obesity / Weight Loss / Fitness
antiaging
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
7 minutes ago
- The Independent
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'


Reuters
38 minutes ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.


Reuters
2 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.